Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KURA 
Kura Oncology Inc (KURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KURA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -4.9% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 569.75M USD | Price to earnings Ratio - | 1Y Target Price 27.69 |
Price to earnings Ratio - | 1Y Target Price 27.69 | ||
Volume (30-day avg) 1149274 | Beta 0.84 | 52 Weeks Range 6.27 - 23.48 | Updated Date 04/1/2025 |
52 Weeks Range 6.27 - 23.48 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -41.67% |
Management Effectiveness
Return on Assets (TTM) -19.97% | Return on Equity (TTM) -42.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -178222033 | Price to Sales(TTM) 10.57 |
Enterprise Value -178222033 | Price to Sales(TTM) 10.57 | ||
Enterprise Value to Revenue 3 | Enterprise Value to EBITDA -2.48 | Shares Outstanding 80755000 | Shares Floating 59769977 |
Shares Outstanding 80755000 | Shares Floating 59769977 | ||
Percent Insiders 1.15 | Percent Institutions 102.19 |
Analyst Ratings
Rating 4.56 | Target Price 28.36 | Buy 3 | Strong Buy 11 |
Buy 3 | Strong Buy 11 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kura Oncology Inc
Company Overview
History and Background
Kura Oncology Inc. was founded in 2014 and is focused on developing and commercializing precision medicines for the treatment of cancer. The company has advanced multiple drug candidates into clinical development, targeting specific cancer-driving pathways.
Core Business Areas
- Drug Development: Focused on the discovery, development, and commercialization of small molecule drugs that target cancer-driving pathways.
Leadership and Structure
Troy Wilson is the current President and CEO. The company has a board of directors overseeing its strategic direction and a management team responsible for day-to-day operations.
Top Products and Market Share
Key Offerings
- Ziftomen (tipifarnib): Ziftomen is an inhibitor of farnesyltransferase (FTase), an enzyme involved in cancer cell growth and survival. It is approved for HRAS-mutant relapsed or refractory acute myeloid leukemia (AML) by the FDA. Market share data is difficult to determine as it just approved, but revenue will be tracked over time. Competitors include standard chemotherapy and other targeted therapies depending on the specific AML subtype.
Market Dynamics
Industry Overview
The oncology therapeutics market is characterized by rapid innovation, high regulatory scrutiny, and intense competition. Precision medicine, focusing on targeted therapies based on specific genetic profiles of tumors, is a major trend.
Positioning
Kura Oncology Inc. is positioned as a precision oncology company developing targeted therapies for specific cancer subtypes. Their competitive advantage lies in their focus on validated cancer targets and their clinical development expertise.
Total Addressable Market (TAM)
The global oncology market is estimated to reach billions of dollars. Kura Oncology's TAM is based on the specific target populations for Ziftomen (tipifarnib) and future pipeline candidates. Their positioning in precision oncology allows it to capture a piece of this TAM. Ziftomen annual sales are estimated to reach hundreds of millions of dollars annually.
Upturn SWOT Analysis
Strengths
- Targeted therapies focus
- FDA approval for Ziftomen
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on single revenue source (Ziftomen)
- Limited commercial infrastructure
- High R&D expenses
- Dependence on successful clinical trials
Opportunities
- Expansion of Ziftomen's indications
- Development of additional pipeline candidates
- Strategic partnerships and collaborations
- Growing demand for precision oncology therapies
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- MRTX
- AZN
- GILD
Competitive Landscape
Kura Oncology Inc. competes with larger pharmaceutical companies that have more established commercial infrastructure. Kura's competitive advantage lies in its targeted therapies and focus on specific cancer subtypes.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical development progress and strategic partnerships.
Future Projections: Future growth is projected to be driven by the commercial launch and market penetration of Ziftomen, as well as the development of additional pipeline candidates.
Recent Initiatives: Recent initiatives include the commercial launch of Ziftomen and ongoing clinical trials for pipeline candidates.
Summary
Kura Oncology is a precision oncology company focusing on developing targeted therapies. The recent FDA approval of Ziftomen is a significant achievement, but the company faces challenges due to limited commercial infrastructure and competition. Future success depends on expanding Ziftomen's indications and advancing pipeline candidates. Financial health depends on effective commercialization and further drug approvals.
Similar Companies
- MRTX
- AZN
- GILD
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kura Oncology Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-09-22 | Chairman, CEO & President Dr. Troy Edward Wilson J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 192 | Website https://kuraoncology.com |
Full time employees 192 | Website https://kuraoncology.com | ||
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.